140 related articles for article (PubMed ID: 33569762)
1. Copeptin is associated with mortality in elderly people.
Smaradottir MI; Andersen K; Gudnason V; Näsman P; Rydén L; Mellbin LG
Eur J Clin Invest; 2021 Jul; 51(7):e13516. PubMed ID: 33569762
[TBL] [Abstract][Full Text] [Related]
2. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.
Khan SQ; Dhillon OS; O'Brien RJ; Struck J; Quinn PA; Morgenthaler NG; Squire IB; Davies JE; Bergmann A; Ng LL
Circulation; 2007 Apr; 115(16):2103-10. PubMed ID: 17420344
[TBL] [Abstract][Full Text] [Related]
3. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study.
Voors AA; von Haehling S; Anker SD; Hillege HL; Struck J; Hartmann O; Bergmann A; Squire I; van Veldhuisen DJ; Dickstein K;
Eur Heart J; 2009 May; 30(10):1187-94. PubMed ID: 19346228
[TBL] [Abstract][Full Text] [Related]
4. Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The British Regional Heart Study.
Wannamethee SG; Welsh P; Lennon L; Papacosta O; Whincup PH; Sattar N
Diabetologia; 2016 Sep; 59(9):1904-12. PubMed ID: 27312697
[TBL] [Abstract][Full Text] [Related]
5. Gender and renal function influence plasma levels of copeptin in healthy individuals.
Bhandari SS; Loke I; Davies JE; Squire IB; Struck J; Ng LL
Clin Sci (Lond); 2009 Feb; 116(3):257-63. PubMed ID: 18647134
[TBL] [Abstract][Full Text] [Related]
6. Copeptin as a biomarker in heart failure.
Balling L; Gustafsson F
Biomark Med; 2014; 8(6):841-54. PubMed ID: 25224940
[TBL] [Abstract][Full Text] [Related]
7. Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities - A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort.
Smaradottir MI; Ritsinger V; Gyberg V; Norhammar A; Näsman P; Mellbin LG
Diab Vasc Dis Res; 2017 Mar; 14(2):69-76. PubMed ID: 28118730
[TBL] [Abstract][Full Text] [Related]
8. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
JAMA; 2011 May; 305(20):2088-95. PubMed ID: 21610241
[TBL] [Abstract][Full Text] [Related]
9. Is the association of serum sodium with mortality in patients with type 2 diabetes explained by copeptin or NT-proBNP? (ZODIAC-46).
Riphagen IJ; Logtenberg SJ; Groenier KH; van Hateren KJ; Landman GW; Struck J; Navis G; Kootstra-Ros JE; Kema IP; Bilo HJ; Kleefstra N; Bakker SJ
Atherosclerosis; 2015 Sep; 242(1):179-85. PubMed ID: 26201002
[TBL] [Abstract][Full Text] [Related]
10. Copeptin and risk stratification in patients with acute dyspnea.
Potocki M; Breidthardt T; Mueller A; Reichlin T; Socrates T; Arenja N; Reiter M; Morgenthaler NG; Bergmann A; Noveanu M; Buser PT; Mueller C
Crit Care; 2010; 14(6):R213. PubMed ID: 21106053
[TBL] [Abstract][Full Text] [Related]
11. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction.
Kelly D; Squire IB; Khan SQ; Quinn P; Struck J; Morgenthaler NG; Davies JE; Ng LL
J Card Fail; 2008 Nov; 14(9):739-45. PubMed ID: 18995178
[TBL] [Abstract][Full Text] [Related]
12. Association of Unrecognized Myocardial Infarction With Long-term Outcomes in Community-Dwelling Older Adults: The ICELAND MI Study.
Acharya T; Aspelund T; Jonasson TF; Schelbert EB; Cao JJ; Sathya B; Dyke CK; Aletras AH; Sigurdsson S; Thorgeirsson G; Eiriksdottir G; Harris T; Launer LJ; Gudnason V; Arai AE
JAMA Cardiol; 2018 Nov; 3(11):1101-1106. PubMed ID: 30304454
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke.
Tu WJ; Dong X; Zhao SJ; Yang DG; Chen H
J Neuroendocrinol; 2013 Sep; 25(9):771-8. PubMed ID: 23701638
[TBL] [Abstract][Full Text] [Related]
14. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
[TBL] [Abstract][Full Text] [Related]
15. C-terminal provasopressin (copeptin) as a prognostic marker after acute non-ST elevation myocardial infarction: Leicester Acute Myocardial Infarction Peptide II (LAMP II) study.
Narayan H; Dhillon OS; Quinn PA; Struck J; Squire IB; Davies JE; Ng LL
Clin Sci (Lond); 2011 Jul; 121(2):79-89. PubMed ID: 21309746
[TBL] [Abstract][Full Text] [Related]
16. Predictive capacity of a multimarker strategy to determine short-term mortality in patients attending a hospital emergency Department for acute heart failure. BIO-EAHFE study.
Herrero-Puente P; Prieto-García B; García-García M; Jacob J; Martín-Sánchez FJ; Pascual-Figal D; Bueno H; Gil V; Llorens P; Vázquez-Alvarez J; Romero-Pareja R; Sanchez-Gonzalez M; Miró Ò
Clin Chim Acta; 2017 Mar; 466():22-30. PubMed ID: 28069402
[TBL] [Abstract][Full Text] [Related]
17. Randomised Assessment of Treatment using Panel Assay of Cardiac markers--Contemporary Biomarker Evaluation (RATPAC CBE).
Collinson PO; Gaze DC; Thokala P; Goodacre S
Health Technol Assess; 2013; 17(15):v-vi, 1-122. PubMed ID: 23597479
[TBL] [Abstract][Full Text] [Related]
18. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.
Richards M; Nicholls MG; Espiner EA; Lainchbury JG; Troughton RW; Elliott J; Frampton CM; Crozier IG; Yandle TG; Doughty R; MacMahon S; Sharpe N; ;
J Am Coll Cardiol; 2006 Jan; 47(1):52-60. PubMed ID: 16386664
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
[TBL] [Abstract][Full Text] [Related]
20. Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes.
Velho G; Ragot S; El Boustany R; Saulnier PJ; Fraty M; Mohammedi K; Fumeron F; Potier L; Marre M; Hadjadj S; Roussel R
Cardiovasc Diabetol; 2018 Aug; 17(1):110. PubMed ID: 30071874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
